Donate

Xtandi In Combination with Zytiga Is Not Better Than Either Drug Alone

A late-stage clinical trial designed to see if Xtandi in addition to Zytiga along with a steroid worked any better than either of these drugs separately (combining them v sequencing them) in men with advanced prostate cancer whose disease had worsened it was concluded that the combination was not superior to the individual drugs. This [...]

Early Hormone Therapy In Men With A Rising PSA Live Longer Then Men Who Delay Therapy – A Phase 3 Trial

The standard of care is to offer androgen deprivation therapy (ADT) to men with prostate cancer who have a rising prostate specific antigen (PSA) after an attempt to cure their cancer with primary therapy that has failed (PSA relapse) or in men who are considered not suitable for curative treatment. The question is what is [...]

Radiotherapy Might Not Extend Survival In Men With Prostate Cancer Who Are Under 70 Years Old

Increasingly, we are seeing younger men diagnosed with prostate cancer and with bone metastases. One of the more common therapies, radiotherapy is recognized for its effect on local control of bone metastases, but whether it could prolong overall survival, the gold standard is still controversial. Researchers retrospectively evaluated 113 men with prostate cancer and bone [...]

Salvage Radical Prostatectomy Improves Long Term Survival in Men with Radiation Recurrent Prostate Cancer

A retrospective study, using the SEER Date, a U.S. national database, analyzed data from men diagnosed with prostate cancer and found that salvage radical prostatectomy (SRP) improved the long-term survival in men whose cancer has returned after receiving radiation therapy. We know that approximately 30% of men who have radiation therapy as their primary therapy will have a recurrence [...]

A new Trend – Chemotherapy for Metastatic Castrate-Sensitive Prostate Cancer

Prostate cancer treatment will change as we incorporate new studies into our clinical practice. One of the major emerging new trends is the earlier use of chemotherapy with androgen therapy (ADT) in men, including men who are still hormone responsive. This changing trend comes from the results from there pivotal randomized phase III trials: GETUG15, [...]

How Quickly You Might Die From Advanced Prostate Cancer Depends On What Organs Are Involved

Researchers at the Duke Cancer Institute along with other cancer centers, in the largest analysis of its kind have found that the organ site where prostate cancer spreads has a direct impact on a man’s survival. They found that men with lymph-only metastasis statistically have the longest overall survival possibility, while those with liver involvement [...]

Combination Chemotherapy And ADT In Hormone Sensitive Prostate Cancer Betters Survival and the Quality Of Life

There is a paradigm shift happening around us in the clinical care of men with metastatic hormone-sensitive prostate cancer. We now know that survival is better when docetaxel chemotherapy is added to androgen-deprivation therapy (ADT), but there have been and still remains concerns about the toxicity of the docetaxel. Recent findings from a new study, [...]

Can Radiotherapy (Radiation) for the Primary Tumors Benefit Men With Prostate CancerWith Distant Metastasis at Initial Diagnosis?

The common belief is that if you are diagnosed with prostate cancer that has already developed metastases only a systemic treatment will provide a life extending benefit. In other cancers it has been shown that the treatment of the primary tumor improves survival (tumor debulking). To find out if, in fact radiotherapy treatment of the [...]

ADT with Radiation Treatment Might Endanger Your Life!

The standard of care and the facts are simple. Men who have aggressive prostate cancer and elect to have radiation therapy will benefit from six months of concurrent hormone therapy (ADT). However, based on recent findings by D’Amico etal, there seems to be a segment of men who will not benefit, but will have inferior [...]

Metabolic Syndrome in Men with Castration-Resistant Prostate Cancer Treated with Abiraterone Affects Their Survival

Yesterday’s post was about the increased risks of developing diabetes faced by men who are on hormone therapy. This study, as well as most others about this topic has looked at the first levels of hormone therapy (ADT) using the traditional drugs like Zoladex, Trelstar, Firmagon, and Lupron. We know very little about the influence [...]

Go to Top